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BRCA1 and BRCA2 are large phosphoproteins involved in DNA-
damage repair through homologous recombination (HR)1. Although 
BRCA1 and BRCA2 share many interacting proteins, they show little 
homology and are thought to have different roles in HR and other 
processes2. BRCA1 is thought to be mainly a scaffold protein ena-
bling interactions between different components of the HR machin-
ery, whereas BRCA2 is directly involved in loading RAD51 to sites of 
damage or stalled replication forks3.
Heterozygous BRCA1 and BRCA2 inactivation mutations are asso-
ciated with an increased risk to develop breast and ovarian cancers. 
These tumors often show loss of heterozygosity of the wild-type allele 
and mutation of the p53 tumor suppressor4,5. Breast cancers that arise 
in BRCA1 mutation carriers are mostly high-grade tumors with the 
so-called triple-negative phenotype (that is, lacking expression of 
estrogen receptor and progesterone receptor and without amplifica-
tion of human epidermal growth factor receptor (ERBB2/HER2))6. 
BRCA1-associated tumors also express basal epithelial cell markers, 
such as cytokeratin 5/6 (ref. 7), and cluster with basal-like breast can-
cers by gene expression profiling8. There is increasing evidence that a 
subset of sporadic tumors with a basal-like/triple-negative phenotype 
may have alterations in BRCA1-related pathways9. In contrast, BRCA2 
mutation carriers develop mostly ER-positive breast cancers.
Whereas BRCA1 and BRCA2 function as tumor suppressors in 
breast and ovarian epithelium, homozygous deletion of BRCA1 or 
BRCA2 appears not to be tolerated during human or mouse develop-
ment and in cultured primary cells such as mouse embryonic fibro-
blasts (MEFs) or stem cells10. Although concomitant deletion of 
p53 partially alleviates these phenotypes11, the incomplete rescue 
suggests the involvement of other factors in BRCA1/2 associated 
cancers. In search for such factors, using a candidate gene approach, 
knockout of 53BP1 was shown in a recent study12 to rescue Brca1 
hypomorphic MEFs and mice from premature senescence. 53BP1, 
a DNA-damage response (DDR) factor involved in both HR and 
nonhomologous end joining (NHEJ), is known to be an activator 
of p53 (ref. 13). However, 53BP1 also has p53 independent func-
tions, and deletion of both 53BP1 and p53 has a synergistic effect 
on tumor development14,15.
The observations in the Brca1 hypomorphic mutants raise some 
intriguing questions. First, will 53BP1 ablation also rescue cells com-
pletely deficient for BRCA1, a situation that is common in BRCA1-
associated tumors? In contrast to Brca1-null mice, the Brca1Δ11/Δ11 
hypomorphic mice still express the natural BRCA1-Δ11 splice vari-
ant, which contains the conserved RING and BRCT domains10. The 
Brca1Δ11 allele is functionally active, as evidenced by the fact that 
homozygous Brca1Δ11/Δ11 mutants are viable on a p53 heterozygous 
background16. Other questions concern the mechanism by which 
deletion of 53BP1 rescues BRCA1-deficient cells and the potential 
relevance of 53BP1 status for BRCA1-associated cancers.
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In this work, we set out to explore these questions. We performed 
an unbiased transposon mutagenesis screen for factors that could 
restore normal growth of Brca1-null cells. Similar to the observations 
with Brca1Δ11 hypomorphic mutants, clonal outgrowth of Brca1-null 
cells was rescued by a loss of function mutation of 53BP1. We show 
that cells lacking both BRCA1 and 53BP1 have a partially restored 
HR pathway. The clinical relevance of these findings is indicated by 
our data showing that 53BP1 expression is reduced in a subset of 
basal-like/triple-negative breast cancers and in BRCA1/2-associated 
breast cancers, suggesting positive selection for loss of 53BP1 func-
tion in these tumors.
RESULTS
53BP1	loss	rescues	proliferation	defects	of	Brca1-null	cells
Brca1 deletion in p53-proficient normal cells leads to a severe prolif-
eration defect17. Cre/loxP-based conditional Brca1 knockout models 
would not be useful to screen for factors that enhance growth of 
BRCA1-deficient cells, as Brca1-deleted cells are rapidly eliminated 
and the culture is rapidly overtaken by BRCA1-proficient cells. To 
overcome this problem, we generated R26CreERT2 Brca1SCo/Δ mouse 
embryonic stem (ES) cells, which contain, in addition to a Brca1Δ5−13-
null allele18, a Brca1 selectable conditional (Brca1SCo) knockout allele 
in which exons 5 and 6 are flanked by loxP recombination sites and 
a split puromycin resistance marker (Fig. 1a and Supplementary 
Fig. 1a). Furthermore, these cells contain the CreERT2 gene targeted 
to the Rosa26 locus, leading to expression of a tamoxifen-inducible 
CreERT2 recombinase fusion protein19. Incubation of these cells with 
4-hydroxytamoxifen (4OHT) resulted in nearly complete switch-
ing of the Brca1SCo allele and consequent loss of BRCA1 protein 
expression (Supplementary Fig. 1b,c). Nonswitched R26CreERT2 
Brca1SCo/Δ cells were effectively removed by puromycin selection 
(Supplementary Fig. 1e).
We used the piggyBac transposon system20 to perform an insertional 
mutagenesis screen for factors that rescue the proliferation defect of 
Brca1-deleted cells (Supplementary Data). We transfected R26CreERT2 
Brca1SCo/Δ ES cells with plasmids containing an engineered piggyBac 
transposon and mouse codon–optimized piggyBac transposase. After 
induction of CreERT2-mediated deletion of the Brca1SCo allele with 
4OHT, we assayed for clonal survival of BRCA1-deficient ES cells 
under puromycin selection (Supplementary Fig. 2a). The majority 
(294 out of 296) of surviving colonies analyzed contained both a 
switched and a nonswitched Brca1SCo allele, indicating strong selection 
for allele duplication events (data not shown). Two clones that were 
completely Brca1 deleted showed identical patterns of piggyBac trans-
poson integrations (Supplementary Fig. 2b), one of which mapped 
to intron 16 of the 53bp1 gene (Supplementary Fig. 2c) and corre-
lated with abrogation of 53BP1 expression (Supplementary Fig. 2d), 
consistent with the reported ability of 53BP1 deletion to abrogate 
senescence and cell death in Brca1Δ11/Δ11 hypomorphic cells12. To 
validate the loss of 53BP1 expression as a survival factor in Brca1-null 
cells, we tested the effects of shRNA-mediated depletion of 53BP1 
in R26CreERT2 Brca1SCo/Δ ES cells with two different shRNAs that 
efficiently suppressed 53BP1 expression, as determined by western 
blot analysis (Fig. 1b). The robust clonal growth arrest of R26CreERT2 
Brca1SCo/Δ ES cells induced by 4OHT treatment was abolished when 
53BP1 was depleted with either shRNA (Fig. 1c).
53BP1	loss	rescues	drug	hypersensitivity	of	Brca1-null	cells
A hallmark of BRCA1-deficient tumors is their cisplatin sensitivity21. 
Consistent with this, we observed enhanced cytotoxicity of cisplatin in 
our Brca1-deleted ES cells (Fig. 1d). shRNA-mediated loss of 53BP1 
fully abolished the cisplatin sensitivity induced by Brca1 inactivation 
(Fig. 1d). We observed a similar reversal of drug sensitivity by 53BP1 
depletion for mitomycin C (Fig. 1e). Although shRNA-mediated inhi-
bition of p53 suppressed the growth defects of Brca1-deleted cells 
(data not shown), it did not suppress cisplatin sensitivity, suggesting 
that p53 and 53BP1 provide distinct pathways for sustaining growth 
arrest in Brca1-deleted cells.
53BP1	loss	blocks	DNA-damage	responses	in	Brca1-null	cells
To investigate how suppression of 53BP1 or p53 alleviates the 
impaired proliferation of Brca1-knockout ES cells, we analyzed cell-
cycle profiles of 4OHT-treated R26CreERT2 Brca1SCo/Δ cells treated 
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Figure 1 Inactivation of 53BP1 rescues proliferation defects  
and drug sensitivity of Brca1-null ES cells. (a) Schematic  
overview of mutant alleles in R26CreERT2 Brca1SCo/Δ and  
R26CreERT2 Brca1Δ/Δ ES cells. Before 4OHT-mediated  
induction of the CreERT2 recombinase, R26CreERT2 Brca1SCo/Δ  
cells are BRCA1 proficient and puromycin sensitive. Addition  
of 4OHT leads to CreERT2-mediated deletion of Brca1  
exons 5 and 6, resulting in BRCA1 inactivation and  
concomitant expression of puromycin from the PGK promoter, thereby enabling selection of BRCA1-deficient R26CreERT2 Brca1Δ/Δ ES cells. (b) Western 
blot analysis of 53BP1 expression in R26CreERT2 Brca1SCo/Δ ES cells nontransduced or transduced with two independent lentiviral shRNA vectors 
against 53bp1, after treatment with 4OHT to delete the Brca1SCo allele. (c) Crystal violet staining of nontransduced R26CreERT2 Brca1SCo/Δ ES cells 
treated with 4OHT and stably transduced with lentiviral vectors expressing a control nontargeting shRNA (NT) or two independent shRNAs against 
53bp1. (d,e) Susceptibility of R26CreERT2 Brca1SCo/Δ ES cells untreated or treated with 4OHT to DNA cross-linking agents cisplatin (d) or mitomycin C (e). 
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 monitored by western blotting (Fig. 2a). In the absence of BRCA1, 
ES cells accumulate in G2 (Fig. 2b), which could reflect a checkpoint 
response induced by accumulation of unrepaired DNA damage. This 
G2 arrest is abrogated in 53BP1-deleted cells but not in p53-depleted 
cells, suggestive of an ataxia-telangiectasia mutated (ATM)-dependent 
checkpoint activation for which 53BP1 is essential. Consistent with 
this, we observed an increase in 53BP1 expression levels in Brca1-
deleted cells (Fig. 2a). The less pronounced effect of p53 depletion on 
the G2 arrest is mirrored by the lower induction of p53 expression in 
response to Brca1 deletion, as detected by western blotting. p53 has 
a major role in the surveillance of chromosome integrity at the G1/S 
transition, although evidence for a relatively weaker p53-dependent 
checkpoint at the G2/M transition has also been reported22,23.
To address the possibility that the loss of 53BP1 affects the DNA 
damage response (DDR) induced by Brca1 deletion, we used MEFs 
that were established from mice carrying a Brca1SCo allele and a 
Brca1Δ5−13-null allele and immortalized by TBX2 overexpres-
sion. Transient expression of Cre recombinase from a self-deleting 
‘hit-and-run’ (H&R) Cre retrovirus24 resulted in efficient deletion of 
Brca1 exons 5 and 6 and loss of BRCA1 expression, as monitored by 
western blotting (Fig. 3a). We detected concomitant loss of 53BP1 
expression when MEFs were co-transduced with the H&R Cre and 
53BP1 shRNA-encoding viruses. Upon Cre-mediated deletion of the 
Brca1 gene, we observed robust phosphorylation of the DNA-damage 
checkpoint kinase CHK2 as well as p53 accumulation, indicative of 
an ATM-dependent DDR in MEFs (Fig. 3a, +Cre, GFPsh). Similar to 
the G2 arrest, this ATM-dependent checkpoint response was mark-
edly attenuated upon 53BP1 inhibition (Fig. 3a, +Cre, 53BP1sh1 
and 53BP1sh2).
Consistent with unrepaired DNA damage being the cause of the 
observed G2/M arrest and checkpoint activation triggered by Brca1 
deletion, we observed a marked increase in chromatid and chromo-
some breaks in BRCA1-deficient MEFs (Fig. 3b). shRNA-mediated 
53BP1 depletion in these cells led to a decrease in the occurrence of 
DNA breaks, reflected in diminished checkpoint responses.
In contrast to Brca1-knockout MEFs, proliferation of Brca2-
knockout MEFs25 was not rescued by shRNA-mediated depletion 
of 53BP1 (Fig. 3c). In contrast, p53 inhibition efficiently restored 
the proliferative capacity of Brca2-deleted cells. Consistent with the 
role of 53BP1 in mediating checkpoint responses specifically in cells 
lacking Brca1, 53BP1 abrogation did not affect CHK2 phosphoryla-
tion in BRCA2-deficient MEFs (Fig. 3d). This observation reflects 
the fundamentally distinct roles played by the BRCA1 and BRCA2 
tumor-suppressor proteins in the DDR: whereas BRCA1 is required 
for the initial steps of the DDR response and signal amplification, 
BRCA2 functions downstream of the checkpoint signaling, promot-
ing the HR pathway of DNA repair. Because 53BP1 acts during the 
early chromatin-remodeling events at the break, it is more likely to 
Figure 2 53BP1 depletion rescues cell-cycle defects of Brca1-null 
ES cells. (a) Western blot analysis of 53BP1 and p53 expression in 
R26CreERT2 Brca1SCo/Δ ES cells stably tranduced with lentiviral shRNA 
vectors against 53bp1 or p53. Samples were taken before or at 4 and 
9 d after 4OHT-induced deletion of Brca1. (b) Flow cytometry profiles 
of R26CreERT2 Brca1SCo/Δ ES cells stably transduced with nontargeting 
shRNA lentiviruses or shRNA vectors against 53bp1 and p53. Shown are 
percentages of cells in G1 and G2 before or 9 d after 4OHT-induced Brca1 
deletion by CreERT2. Mean ± s.d. is shown from two experiments.
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Figure 3 53BP1 depletion abrogates CHK2-mediated DNA-damage 
responses and rescues proliferation defects in Brca1-null but not Brca2-
null MEFs. (a) Western blot analysis of cell extracts from Brca1SCo/Δ MEFs 
infected with retroviruses expressing self-deleting Cre recombinase (+Cre) 
or empty vector (−Cre) together with retroviruses expressing 53BP1 or 
GFP control shRNAs. SMC1 and tubulin were used as loading controls. 
NSB, nonspecific band. (b) Quantification of chromatid and chromosome 
break frequency in metaphase spreads prepared from cells treated as in a.  
At least 100 metaphases were scored for each sample. Shown is the 
average number of events per metaphase ± s.d. (c) Proliferation curves 
of Brca1SCo/Δ or Brca2F/Δ MEFs infected with retroviruses expressing 
self-deleting Cre recombinase (+Cre) or empty vector (−Cre) together with 
retroviruses expressing p53, 53BP1 or GFP control shRNAs. (d) Western 
blot analysis of cell extracts from Brca2F/Δ MEFs treated as in c. Tubulin 
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affect BRCA1-dependent signaling. In contrast, BRCA2 activation 
requires the damage signal generated at the break to be transduced 
downstream through at least two parallel pathways involving several 
response factors26. Thus, the loss of 53BP1 can be compensated by 
other regulatory mechanisms acting between the early events at the 
chromatin surrounding the break and the initiation of repair reac-
tions. Although shRNA-mediated depletion of p53 rescues the pro-
liferation defect of BRCA2-deficient cells, DDR activation shown by 
CHK2 phosphorylation persists. This suggests that CHK2-mediated 
p53 activation contributes to the senescence response induced by 
the loss of BRCA2. Consistent with the role of BRCA2 as the loader 
of RAD51 onto double-strand breaks (DSBs), the initiating step of 
recombinational DNA repair, we did not detect any rescue of RAD51 
foci in BRCA2-deficient cells when either p53 or 53BP1 were depleted 
(data not shown).
Together, these results suggest that 53BP1 is required for efficient 
ATM-dependent checkpoint signaling to arrest cell-cycle progres-
sion in response to DNA damage accumulation in Brca1-deleted cells. 
Alternatively, 53BP1 loss might lead to more efficient DNA DSB repair 
and thereby reduce DDR activation.
53BP1	loss	partially	restores	HR	in	Brca1-null	cells
The observed abrogation of G2 accumulation, sensitivity to DNA cross-
linkers and DDR may be due to a stimulation of BRCA1-independent 
DNA repair. Alternatively, checkpoint release might prevent the forma-
tion of DNA breaks by collapsing replication forks or allow the cells to 
continue cycling without actual repair of the damage. To investigate 
the effects of 53BP1 depletion on DNA repair, we analyzed RAD51 
focus formation in Brca1SCo/Δ and Brca1Δ/Δ ES cells following treat-
ment with ionizing irradiation (Fig. 4). Analysis of these ionizing 
radiation–induced RAD51 foci revealed a diminished response upon 
deletion of Brca1 (Fig. 4a,c), consistent with previous observations27. 
shRNA-mediated depletion of 53BP1 enhanced RAD51 focus forma-
tion in the absence of BRCA1, suggesting upregulation of HR in a 
BRCA1-independent manner. This process is not specific for ES cells, 
as we observed the same phenomenon in MEFs (Fig. 4b,d).
To determine whether 53BP1 depletion rescues homology-directed 
repair (HDR) in BRCA1-deficient cells, we measured gene-targeting 
efficiencies in R26CreERT2 Brca1SCo/Δ ES cells with or without shRNA-
mediated depletion of 53BP1 or p53 using an isogenic Rb-targeting 
construct with a PGK-neo selection marker28. Whereas CreERT2-
mediated deletion of Brca1 by addition of 4OHT abolished Rb gene 
targeting in R26CreERT2 Brca1SCo/Δ ES cells, this effect could not be 
reversed by shRNA-mediated depletion of p53 (Table 1). In contrast, 
we observed correct integration of the targeting vector at the Rb locus 
in 2 out of 160 53BP1-depleted R26CreERT2 Brca1Δ/Δ ES cell colonies 
compared to 8 out of 78 R26CreERT2 Brca1SCo/Δ colonies, suggesting 
that 53BP1 loss leads to partial restoration of HDR in Brca1-null cells. 
This notion was supported by gene-targeting experiments with a pro-
moterless Pim1-neo targeting construct29, showing correct integra-
tion in 4 out of 47 53BP1-depleted R26CreERT2 Brca1Δ/Δ ES colonies 
compared to 9 out of 56 R26CreERT2 Brca1SCo/Δ colonies (Table 1). We 
conclude that depletion of 53BP1 restores HR activity in Brca1-null 
cells to 10–50% of that of BRCA1-proficient cells.
Basal-like	breast	cancers	have	low	levels	of	53BP1
The majority of BRCA1-associated tumors carry p53 mutations30,31. 
It is known that p53 loss can at least partially rescue BRCA1-deficient 
cells11,32. However, there may still be additional selection for aberrant 
expression of 53BP1, as suggested by our in vitro results and by the 
synergism in tumorigenesis observed in 53bp1−/−p53−/− knockout 
mice14,15. Therefore, we analyzed levels of 53BP1 mRNA in a publicly 
Table 1 Gene-targeting frequencies in R26CreERT2 Brca1SCo/Δ  
ES cells
G418-resistant colonies
4OHTa shRNA Total analyzed Nontargeted (%) Targeted (%)
Rb − NT 78 70 (90) 8 (10)
+ NT 78 78 (100) 0 (0)
+ 53BP1 160 158 (99) 2 (1)
+ p53 124 124 (100) 0 (0)
Pim1 − NT 56 47 (84) 9 (16)
+ NT 11 11 (100) 0 (0)
+ 53BP1 47 43 (91.5) 4 (8.5)
a4-hydroxytamoxifen (4OHT) was added to induce deletion of Brca1SCo.
Figure 4 53BP1 depletion rescues RAD51 foci in Brca1-null cells.  
(a) RAD51 focus formation in R26CreERT2 Brca1SCo/Δ ES cells untreated 
or treated with 4OHT and transduced with lentiviruses expressing 
nontargeting shRNAs (NTsh) or shRNAs targeting 53bp1 (53BP1sh). Cells 
were irradiated with 10 Gy, fixed after 6 h and stained with anti-RAD51 
antibody (red). Nuclei were visualized with 4′,6-diamidino-2-phenylindole 
(DAPI) (blue). (b) RAD51 focus formation in Brca1SCo/Δ MEFs infected 
with retroviruses expressing self-deleting Cre recombinase (+Cre) or 
empty vector (−Cre) together with retroviruses expressing 53BP1 or GFP 
control shRNAs. Cells were irradiated with 10 Gy, fixed after 2 h and 
stained with anti-γH2AX (red) and anti-RAD51 antibodies (green). Nuclei 
were visualized with DAPI (blue). (c) Quantification of RAD51 foci in 
R26CreERT2;Brca1SCo/Δ ES cells treated as in a. At least 20 nuclei were 
analyzed for each treatment. (d) Quantification of RAD51 foci in Brca1SCo/
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available database of gene expression array data from 286 breast 
 cancer specimens33, all early stage (lymph-node negative) and treated 
with surgery and radiation therapy alone. We used previously 
described unsupervised clustering methods to identify basal-like 
breast cancers (BLCs), HER2-positive breast cancers and luminal A 
and luminal B subclasses of breast cancer34. BLC tumors are char-
acterized clinically as high-grade, invasive breast cancers that lack 
expression of estrogen receptor, progesterone receptor and HER2 
(triple-negative phenotype) and are associated with a younger age of 
onset. Luminal tumors are characterized by expression of the estrogen 
receptor (ER+), with luminal A tumors being mostly low-grade ER+ 
tumors and luminal B tumors being mostly high-grade ER+ tumors. 
We next calculated mean levels of 53BP1 expression for each breast 
cancer subtype (Fig. 5a). We found the lowest 53BP1 expression levels 
in the BLC subclass.
We have previously shown that a robust consensus clustering 
approach of breast cancer gene-expression data reveals two subclasses 
of BLC, which we labeled BA1 and BA2 (ref. 34). This approach also 
identifies two subclasses of HER2-positive cancers and three sub-
classes of luminal B tumors. We examined 53BP1 mRNA expression 
in these different subclasses in a combined dataset that includes the 
published datasets of two previous reports33,35. In this combined 
dataset, we found that 53BP1 expression was clearly lowest in the 
BA1 subtype of BLC (P < 0.0001 versus normal, P < 0.0002 versus 
BA2) (Fig. 5b). These data suggest that a biologically relevant subset 
of BLC has low 53BP1 expression. To validate this finding at the pro-
tein level, we assayed a set of 504 breast cancer specimens from the 
Yale cohort by immunohistochemistry on tissue microarrays. The 
clinical characteristics of the tumors in this collection are shown in 
Supplementary Table 1. Four hundred forty-four cases were evalu-
able for 53BP1 status. We scored a specimen as lacking 53BP1 staining 
if <10% of tumor cells showed nuclear staining with this antibody 
(Supplementary Fig. 3). Out of 444 evaluable breast cancer speci-
mens, we scored 65 (14.6%) as being negative for 53BP1.
53BP1	loss	is	associated	with	triple-negative	phenotype
In the Yale cohort of 444 tumors, lack of 53BP1 staining correlated 
independently with lack of estrogen receptor expression, lack of pro-
gesterone receptor expression and lack of HER2 overexpression, as 
assessed by immunohistochemistry (Table 2). There was a striking 
correlation between the absence of 53BP1 staining and the triple-
negative phenotype, defined as being ER-, PR- and HER2-negative. 
Of the 63 tumors in the Yale cohort that lacked 53BP1 staining and 
for which ER, PR and HER2 status were available, 57 (90.5%) of 
these tumors were triple-negative tumors. Of the 132 triple-negative 
tumors assayed, 57 (43%) were 53BP1 negative, whereas of the 311 
non–triple-negative tumors, only 6 (2%) had reduced 53BP1 stain-
ing. This correlation was statistically significant (P < 0.0001). The 
immunohistochemistry data are consistent with the gene-expression 
data and confirm that a subset of BLCs and triple-negative tumors 
have a profoundly decreased 53BP1 expression. Loss of 53BP1 was 
associated with age below 50, with most (67%) of 53BP1-negative 
tumors occurring in women less than 50 years old. There was no 
correlation with tumor size, lymph-node status or race.
53BP1	loss	is	associated	with	BRCA1/2	mutation	status
To validate and extend the data from the Yale cohort, including assess-
ment of 53BP1 protein expression in BRCA1/2-mutated familial breast 
carcinomas, we performed an independent larger-tissue microarray 
analysis on the Helsinki cohort of 1,187 patients (Table 3). We obtained 
these data using different 53BP1 antibodies, and the data were analyzed 
independently by separate pathologists (see Supplementary Fig. 4  
for examples of 53BP1 staining patterns in the Helsinki cohort). 
Confirming the results obtained from the Yale cohort, lack of 53BP1 
staining in the Helsinki cohort correlated independently with lack 
of estrogen receptor expression (P = 0.000004), lack of progesterone 
receptor expression (P = 0.003) and the triple-negative phenotype 
a
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Figure 5 53BP1 expression is reduced in a subset of human  
BLC. (a) Boxplots showing 53BP1 expression levels among  
breast cancer subtypes. Gene expression array data from 286  
early-stage breast cancers33 were clustered to classify tumors  
into basal (BA), HER2-positive (HER2), luminal A (LA) and  
luminal B (LB). The mean expression values of 53BP1 are shown  
for each subgroup. (b) Boxplots showing 53BP1 expression levels 
among different breast cancer subtypes defined by robust  
consensus clustering: normal (NM), basal (BA1, BA2), HER2- 
positive (HER2I, HER2NI), and luminal (LA, LB1, LB2, LB3).  
The data are normalized, with mean expression of the combined  
data being set to 0. Expression of 53BP1 is significantly lower in  
the BA1 subtype (P < 0.0001 versus normal; P < 0.0002 versus  
BA2). (c,d) Distant relapse–free survival stratified by 53BP1  
protein expression in all breast cancers (c) and in triple-negative (TN) 
breast cancers (d). Kaplan-Meyer survival curves are shown for breast 
cancers that scored positive for 53BP1 staining (black lines) and those 
that scored negative for 53BP1 staining (red lines).
Table 2 Low 53BP1 expression correlates with triple-negative 
status (Yale cohort)
53BP1 expression
Features Total (%) Positive (%) Negative (%) Pa
Estrogen receptor
 Positive 243 (55) 239 (63) 4 (6)
 Negative 200 (45) 140 (37) 60 (94) <0.0001
Progesterone receptor
 Positive 226 (51) 222 (59) 4 (6)
 Negative 217 (49) 157 (41) 60 (94) <0.0001
ERBB2/HER2
 Positive 78 (18) 77 (20) 1 (2)
 Negative 366 (82) 303 (80) 63 (98) <0.0001
Triple-negative (TN)
 Not TN 311 (70) 305 (80) 6 (10)
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(P = 0.000004). In addition, the familial tumors from BRCA1/2 
mutation carriers (79 tumors) showed the highest degree of aberrant 
53BP1 reduction or loss compared to sporadic tumors (n = 374, 
P = 0.000003), familial carcinomas not attributable to BRCA1/2 muta-
tions (n = 734, P = 0.001) or all non-BRCA1/2 tumors (n = 1,108, 
P = 0.0001). Both BRCA1- and BRCA2-associated tumors showed 
a significantly increased incidence of reduced 53BBP1 staining 
compared to non-BRCA1/2 tumors (P = 0.003 for BRCA1 and 
P = 0.008 for BRCA2). Overall, these results show that loss of 53BP1 is 
more frequent among the most aggressive and difficult-to-treat triple-
negative tumors as well as in tumors with BRCA1/2 mutations.
53BP1	expression	and	distant	metastasis–free	survival
We analyzed the survival data from the Yale cohort. There was 
significant association between 53BP1 status and distant metastasis– 
free survival, with 53BP1-negative tumors having significantly lower 
metastasis-free survival (Fig. 5c) (P = 0.001). As most tumors that 
lack 53BP1 have a triple-negative phenotype, we analyzed distant 
metastasis–free survival in triple-negative breast cancers stratified 
by 53BP1 status. Amongst the triple-negative tumors, those that 
lack normal 53BP1 staining have decreased metastasis-free survival 
(P = 0.039) (Fig. 5d). As the cancers in this dataset were mostly early-
stage, lymph node–negative cancers that did not receive any adjuvant 
treatment, these data suggest that early-stage triple-negative tumors 
with reduced 53BP1 may have a greater likelihood of metastasis in 
the absence of systemic treatment compared to triple-negative tumors 
with intact 53BP1.
DISCUSSION
BRCA1 is a large ubiquitously expressed protein that has a major 
role in DDR by HR. Its activity is extensively regulated by phos-
phorylation36, sumoylation37–39 and interactions with many other 
proteins. Perhaps not surprisingly, BRCA1 is not only involved in 
HR but also in many other processes like cell-cycle control and tran-
scriptional regulation39,40. Despite its widespread expression and 
non–cell type–specific functions, mutations in BRCA1 are mainly 
associated with increased risk of breast and ovarian tumorigenesis. 
Loss of BRCA1 leads to severe proliferation defects in normal, non-
cancerous cells—for instance, leading to lethality during embryonic 
development. Therefore, it seems likely that there are survival factors 
that allow BRCA1-deficient tumor cells to expand. In an unbiased 
genetic screen, we found that loss of 53BP1 rescues clonal outgrowth 
of Brca1-null ES cells. This result confirms the recently described 
rescue of Brca1Δ11/Δ11 hypomorphic mice by 53BP1 knockout12. 
In addition, it shows that expression of the BRCA1-Δ11 splice 
 variant is not required for rescue of BRCA1 deficiency by 53BP1 
loss. This is important, as many human BRCA1-associated cancers 
are characterized by complete loss of BRCA1 expression. Further 
characterization indicated that BRCA1 and 53BP1 double-deficient 
cells are no longer hypersensitive to DNA cross-linking agents and 
do not spontaneously form DSBs or activate DDR. Suppression of 
ionizing radiation–induced CHK2 phosphorylation has been previ-
ously observed upon RNA interference–mediated 53BP1 depletion 
in U2OS cells13 and in 53bp1−/− MEFs41. Here we show that 53BP1 
status specifically affects the spontaneous induction of CHK2 phos-
phorylation when BRCA1 is lost. Our results are consistent with 
recently reported data on 53BP1-mediated suppression of DNA 
resection at DSBs and accumulation of single-stranded DNA ends 
in BRCA1 and 53BP1 double-deficient cells42. In cell-free extracts, 
DNA damage–induced ATM activation and CHK2 phosphorylation 
are inhibited by 3′ single-stranded DNA overhangs generated during 
DNA-break processing in S/G2 (ref. 43). The decreased CHK2 
phosphorylation that we observed in 53BP1-depleted Brca1-null 
cells could therefore result from decreased ATM signaling due to 
increased DNA resection or from increased DSB repair. The latter 
possibility is supported by the restoration of ionizing radiation–
induced RAD51 focus formation and the partial restoration of HR 
in 53BP1-depleted Brca1-null cells.
Although our data suggest that a certain level of HR repair can 
take place in the absence of both BRCA1 and 53BP1, 53BP1-depleted 
Brca1-null cells remain HR defective, as gene-targeting frequencies 
in these cells are reduced by a factor of 2–10 when compared to wild-
type cells. Consistent with this, BRCA1-deficient tumors show excel-
lent responses to therapies exploiting a HR defect, such as platinum 
drugs44 or PARP inhibitors45. Also, Brca1-mutated mouse mammary 
tumors are highly sensitive to treatment with PARP inhibitors46 or 
platinum drugs47. Whereas human BRCA1-mutated tumors can 
develop resistance to carboplatin by genetic reversion of the BRCA1 
mutation48—stressing the importance of BRCA1 function for HR—
mouse mammary tumor models with large deletions in Brca1 cannot 
employ this mechanism and remain sensitive to cisplatin or carbopla-
tin, even after multiple rounds of treatment47. In contrast, Brca1Δ11/Δ11 
mouse mammary tumors, which only express the BRCA1-Δ11 iso-
form, readily become resistant to cisplatin despite the fact that Brca1 
exon 11 sequences are irreversibly deleted49. This feature might be 
indicative of residual activity of the BRCA1-Δ11 isoform in HR.
At present, it is not clear whether 53BP1 loss contributes to develop-
ment, therapy response and/or acquired resistance of BRCA1-deficient 
tumors. To explore this, we examined 53BP1 expression in independent 
cohorts of breast cancer patients from the US and Finland. These two 
tumor sets were analyzed by different antibodies and reviewed by inde-
pendent pathologists using separate criteria, yet both cohorts showed a 
striking correlation of low 53BP1 expression levels with triple-negative 
Table 3 Loss or reduction of 53BP1 expression correlates  
with triple-negative status and BRCA1/2 mutation status  
(Helsinki cohort)
53BP1
Features Total (%) Normal (%) Aberrant (%) Pa
Estrogen receptor 1,053
 Positive 834 (79.2) 823 (80.3) 11 (39.3)
 Negative 219 (20.8) 202 (19.7) 17 (60.7) 0.000004
Progesterone receptor 1,050
 Positive 703 (67.0) 692 (67.7) 11 (39.3)
 Negative 347 (33.0) 330 (32.3) 17 (60.7) 0.003
ERBB2/HER2 1,075
 Positive 145 (13.5) 142 (13.6) 3 (10.3)
 Negative 930 (86.5) 904 (86.4) 26 (89.7) 0.8
Triple-negative (TN) 1,018
 Not TN 875 (86.0) 861 (87.0) 14 (50.0)
 TN 143 (14.0) 129 (13.0) 14 (50.0) 0.000004
BRCA1/2 mutation 1,187
 Non-BRCA1/2 1,108 (93.4) 1,079 (94.0) 29 (74.4) 0.000003b
 Sporadic 374 371 3 0.001c
 Familial non-BRCA1/2 734 708 26
 BRCA1/2 79 (6.6) 69 (6.0) 10 (25.6) 0.0001d
 BRCA1 35 30 5 0.003e
 BRCA2 44 39 5 0.008f
aFisher’s exact test. bBRCA1/2 versus sporadic. cBRCA1/2 versus familial non-BRCA1/2 
tumors. dBRCA1/2 vs. all non-BRCA1/2 tumors (sporadic + familial non-BRCA1/2). 
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tumors. Since most BRCA1-mutated breast cancers cluster in this sub-
group, it was not unexpected to find that these tumors also lacked 53BP1 
expression more often than other subsets of breast tumors. However, the 
often hormone receptor–positive BRCA2-associated tumors were also 
significantly enriched for 53BP1 aberrations. This may be indicative of 
a common selection for 53BP1 ablation in both types of HR-deficient 
breast cancers. This might occur via different routes, given the per-
sistence of DDR activation and growth impairment in 53BP1-depleted 
BRCA2-deficient cells.
In conclusion, we have shown that 53BP1 loss alleviates the prolif-
eration defect and DNA-damage hypersensitivity of Brca1-null cells 
and leads to partial restoration of HR in these cells. Furthermore, 
aberrant expression of 53BP1 is more common in BRCA1/2 associ-
ated breast cancers, which may hint at a role for 53BP1 loss in these 
tumors. 53BP1 is also lost in a subset of sporadic triple-negative breast 
cancers, suggesting a broader role for abnormalities in this pathway 
in breast tumorigenesis. Our results suggest that loss of 53BP1 may 
promote survival of BRCA1-deficient tumor cells after DNA damage 
induced by chemotherapy or irradiation. It is possible that 53BP1 loss 
may have different effects in BRCA1-deficient tumors versus sporadic 
triple-negative breast cancers. Regardless, 53BP1 might represent a 
candidate biomarker for predicting the response of HR-defective 
tumors to PARP inhibitors or platinum drugs.
METHODS
Methods and any associated references are available in the online 
version of the paper at http://www.nature.com/nsmb/.
Note: Supplementary information is available on the Nature Structural & Molecular 
Biology website.
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ONLINE	METHODS
R26CreERT2 Brca1SCo/D ES cells and mutagenesis screen. Details on the genera-
tion of R26CreERT2 Brca1SCo/Δ ES cells and the piggyBac transposon mutagenesis 
screen are described in Supplementary Methods.
MEF isolation and immortalization. Heads and organs of E13.5 embryos were 
removed, and the remaining tissue was minced, rinsed in PBS and incubated for 
30 min in 0.5 ml 0.05% (w/v) trypsin-EDTA (GIBCO) at 37 °C. Cell aggregates 
were dissociated in DMEM supplemented with 10% (v/v) FBS (GIBCO) and 
penicillin-streptomycin (GIBCO). Cells were plated on 10-cm dishes and cryo-
preserved after 2 d as passage 1 MEFs. MEFs were immortalized by infection 
with TBX2 retrovirus50.
Retroviral transductions. MEFs were transduced with pRetroSuper retroviruses 
encoding shRNAs targeting GFP51, 53BP1 (sh1, 5′-GCTATTGTGGAGATT 
GTGTTT-3′; sh2, 5′-GCGTAGAAGATATTTCACCTA-3′) or p53 (ref. 52) as 
described previously53 (Supplementary Table 2). Briefly, HEK 293T packaging 
cells were transfected with pCL-Eco helper vector together with either pRetroSuper 
alone or pRetroSuper plus retroviral vector encoding H&R Cre recombinase24. The 
culture medium was replaced 24 h after transfection. Recipient MEFs were plated 
and then were infected 24 h later with retroviral supernatants. Additional infections 
were performed after 24 and 32 h. Twenty-four hours after the last infection, cells 
were washed and grown in medium containing 2–3 mg ml−1 puromycin.
Lentiviral transductions. R26CreERT2 Brca1SCo/Δ ES cells were transduced 
with pLKO-puro shRNA lentiviruses obtained from Mission library clones 
(Sigma). In addition to the 53BP1 shRNAs mentioned above, we used 
shRNAs targeting p53 (sh1, 5′-CTACAAGAAGTCACAGCACAT-3′; sh2, 
5′-AGAGTATTTCACCCTCAAGAT-3′) and a nontargeting shRNA (SHC202, 
5′-CAACAAGATGAAGAGCACCAA-3′) (Supplementary Table 2). After selec-
tion with 1.8 μg ml−1 puromycin, cells were switched by overnight incubation 
with 0.5 μM 4OHT. Four days after switching, cells were seeded at 1,000 cells cm−2 
and assayed for clonal growth. Surviving colonies were fixed in formalin and 
stained with crystal violet.
Cell-cycle analysis. Cells were incubated with BrdU for 1 h, fixed with ethanol 
and incubated with mouse anti-BrdU (clone BU20A, Dako) and goat anti–mouse 
FITC conjugated secondary antibodies (DAKO). Cell-cycle distribution was 
measured by flow cytometry and analyzed using FlowJo software (FlowJo).
Cytotoxicity assays. R26CreERT2 Brca1SCo/Δ ES cells were seeded in triplicate at 
1,000 or 3,000 (in the case of switched cells with nontargeting shRNA) cells per 
well in 96-well plates. One day after seeding, cells were fed with medium contain-
ing either cisplatin or mitomycin C. Five days later, cell viability was assayed in an 
Envision plate reader (Perkin Elmer) using resazurin (cell titer blue, Promega).
MEF proliferation assays. Primary MEFs were seeded at 5,000 cells per well in 96-well 
plates. Cell number was determined after 24, 48, 72 and 96 h by incubat-
ing cells with 10 micrograms ml−1 resazurin. After 2 h, fluorescence was 
measured at 590 nm using a microtiter plate reader (2103 multilabel reader, 
Perkin Elmer).
Analysis of chromosomal aberrations. Exponentially growing MEFs were either 
collected and processed for immunoblotting as described below or processed 
for metaphase spreads preparation. For this, cells were treated with 0.1 μg ml−1 
colcemid for 4 h or 16 h, trypsinized, swollen in hypotonic buffer (10 mM Tris-
HCl, pH7.5, 10 mM NaCl, 5 mM MgCl2) at 37 °C for 5 min and fixed in 3:1 
methanol:glacial acetid acid.
Immunoblotting. Cells were harvested by trypsinization, washed twice with cold 
HBSS, resuspended in SDS-PAGE loading buffer and sonicated. Equal amounts 
of protein were analyzed by gel electrophoresis followed by western blotting. 
NuPAGE-Novex 10% (w/v) bis-Tris gels or Tris-acetate 3–8% (w/v) (Invitrogen) 
were run according to the manufacturer’s instructions.
Immunofluorescence. ES cells were grown on coverslips, γ-irradiated with 
10 Gy and fixed 6 h later using 2% (w/v) paraformaldehyde in PBS. Fixed cells 
were incubated with antibody in PBS containing 0.5% (w/v) BSA and 0.15% (w/v) 
glycine, mounted using Vectashield with 4,6-diamidino-2-phenylindole (DAPI) 
(Vector Laboratories) and imaged with a Hamamatsu ORCA AG CCD camera 
on a Zeiss Axio Observer Z1 system. For quantification of RAD51 foci, images 
were converted into 8-bit gray-scale pictures using Image J software (ImageJ, US 
National Institutes of Health), and the fluorescence-intensity threshold was set 
based on a black-and-white intensity scale from 140 to 255. For each sample, the 
number of foci was counted in at least 20 individual nuclei.
MEFs were grown on coverslips and γ-irradiated with 10 Gy. Cells were allowed 
to recover for the indicated times, washed in PBS and swollen in hypotonic solu-
tion (85.5 mM NaCl, 5 mM MgCl2, adjusted to pH 7.0) for 5 min. Cells were 
fixed with 4% paraformaldehyde (10-min at room temperature), permeabilized 
by adding 0.03% (w/v) SDS to the fixative and immunostained as described54. 
Dried coverslips were mounted on microscope slides using the ProLong Antifade 
kit (Invitrogen) supplemented with 1 mg ml−1 DAPI, and viewed with a Leica 
DMI6000B fluorescence microscope. Images were acquired with a Leica DFC350 
FX R2 digital camera using LAS-AF software (Leica). Image brightness and con-
trast were adjusted using Photoshop CS3 (Adobe). To quantify RAD51 foci, we 
determined the frequency of nuclei with more than 10 RAD51 foci. At least 50 
nuclei were analyzed for each sample.
Antibodies. Antibodies used for immunoblotting of ES cells were mouse 
monoclonal anti–mouse BRCA1 (GH118), affinity-purified rabbit polyclonal 
anti–mouse BRCA1 against peptide 452–469, 53BP1 (ab21083, Abcam) and p53 
(IMX25, Monosan). Immunocytochemical staining of ES cells was performed 
using human RAD51 (ref. 54) and goat anti–rabbit Alexa 588 secondary antibody 
(Molecular Probes).
Antibodies used for immunobloting of MEFs were human RAD51 (ref. 54), 
SMC1 (BL308, Bethyl), 53BP1 (NB100-304, Novus), p53 (1C12, Cell Signaling), 
Chk2 (clone 7, Millipore) and α-tubulin54 (CRUK Monoclonal Antibody Service). 
Antibodies for imunofluorescence staining of MEFs were mouse monoclonal 
anti–phospho histone H2AX-Ser139 (Upstate Biotechnology) and RAD51 (H-92, 
Santa Cruz biotechnologies).
Gene-targeting assays. R26CreERT2 Brca1SCo/Δ ES cells were electroporated with 
linearized Rb-neo28 or Pim1-neo29 targeting constructs. After drug selection with 
200 μg ml−1 G418, colonies were picked, expanded and lysed in direct lysis rea-
gent (Viagen) containing 100 μg ml−1 proteinase K. Following heat inactivation of 
proteinase K, genomic DNA was used for PCR analysis or digested with appropri-
ate restriction enzymes and analyzed by Southern blotting as described28,29.
Analysis of 53BP1 expression in human breast cancers. Details on analysis of 
53BP1 expression in human breast cancers using tissue microarrays from the Yale 
and Helsinki cohorts or gene expression array datasets from previous reports33,35 
are described in Supplementary Methods.
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